RISK FACTORS FOR SARS-COV-2 INFECTION AND PECULIARITIES OF VIRAL SHEDDING IN PATIENTS WITH SARCOIDOSIS


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Objective. To study risk factors for SARS- CoV-2 in patients with sarcoidosis (S) and the features of viral shedding in them during the development of COVID-19. Subjects and methods. Nineteen case histories of S patients who had fallen ill with COVID-19 were analyzed. The diagnosis of S was confirmed morphologically, whereas COVID-19 was confirmed mainly by positive PCR tests for SARS-CoV-2 RNA. Mediastinal, pulmonary-and-mediastinal, and pulmonary S were diagnosed in 11, 6, and 2 cases, respectively. Sixteen patients with S before COVID-19 had a stable clinical condition that required no medical support. In unstable S, 1 patient took azathioprine (100 mg/day) and two had metypred (8 mg/day). As a result of treatment, all the patients with S recovered from COVID-19. All the 19 patients underwent an epidemiological analysis that included an assessment of the likely sources of SARS-CoV-2. Results. The patients with S were found to have contacts for coronavirus: familial (n = 8), working (n = 6), nosocomial (n = 3), household (n = 1), and unidentified (n = 1) contacts. The mean duration of viral shedding was 10.6±2.8 days in the Spatients. Six patients with S had mild COVID-19; 13 had a moderate course with recovery. Conclusion. The main risk factors for SARS-CoV-2 infection in S are familial and working contacts: being in the same room with the source of infection and professional activities associated with numerous contacts with a large number of people. COVID-19 in Spatients was characterized by its mild and moderate clinical course. The mean duration of viral shedding in this case was 10.6±2.8 days.

全文:

受限制的访问

作者简介

Vitaly Dobin

Academician I.P. Pavlov Ryazan State Medical University, Ministry of Health of Russia

Email: viladob@gmail.com
MD, Professor, Department of Infectious Diseases and Phthisiology Ryazan, Russia

Ilya Panin

Academician I.P. Pavlov Ryazan State Medical University, Ministry of Health of Russia

Email: iliavpanin@gmail.com
Cand. Med. Sci., Assistant Professor, Department of Cardiovascular, X-Ray Endovascular Surgery and Radiodiagnosis Ryazan, Russia

Vladimir Martynov

Academician I.P. Pavlov Ryazan State Medical University, Ministry of Health of Russia

Email: dr.martinov@mail.ru
MD, Head, Department of Infectious Diseases and Phthisiology Ryazan, Russia

参考

  1. Добин В.Л., Панин И.В. Саркоидоз и COVID-19. Туберкулез и болезни легких 2021; 99 (8): 7-12. doi.org/10.21292/2075-1230-2021-99-8-7-12
  2. Визель А.А., Визель И.Ю., Костинов М.Л., Амиров Н.Б. Саркоидоз. Новая инфекция COVID-19 и вопросы вакцинации. Вестник современной клинической медицины 2021; 14 (4): 48-57. DOI: 10.20969/ VKSM.2021.14(4).48-57
  3. Manansala M., Ascoli C., Alburquerque A.G., Perkins D., Mirsaedi M., Finn P., Sweiss N.J. Case Series: COVID-19 in African American Patients With Sarcoidosis. Front Med. (Lausanne) 2020; (7): 588527. doi: 10.3389/fmed.2020.588527. PMID: 33251236;PMCID: PMC767220
  4. Morgenthau A.S., Levin M.A., Freeman R., Reich D.L., Klang E. Moderate or Severe Impairment in Pulmonary Function is Associated with Mortality in Sarcoidois Patients Infected with SARS-CoV-2. Lung 2020; 198 (5): 771-5. doi: 10.1007/s00408-020-00392-9
  5. Baughman R.P., Buchanon M., Rottoli P. et al. Risk and outcome of COVID-19 infection in sarcoidosis patients: results of a self-reporting questionnaire. Sarcoidosis Vasc Lung Dis. 2020; 37: e2020009. doi: 10.36141/svdld.v37i4.10726
  6. Sweiss N.J., Korsten P., Syed H.J., Syed Aamer, Culver D.A., Sosenko T. et al. When the game changes: guidance to adjust sarcoidosis management during the COVID-19 pandemic. Chest 2020; 158 (3). doi: 10.1016/j.chest.2020.04.033

补充文件

附件文件
动作
1. JATS XML

版权所有 © Bionika Media, 2022
##common.cookie##